Navigation Links
Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430
Date:9/16/2013

ATLANTA, Sept. 16, 2013 /PRNewswire/ -- Atlanta-based pharmaceutical discovery and development company, Celtaxsys, Inc., announced today the achievement of a significant clinical milestone for its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis (CF) lung disease. Celtaxsys has successfully completed the first of two clinical trials in its Phase 1 program, and the first trial conducted through its Australia subsidiary, Celtaxsys Aus Pty Ltd. In this First-in-Human trial, CTX-4430 was administered orally to Healthy Volunteers in escalating doses (up to 200 mg/day for 2 weeks) and was well-tolerated at all doses. Results of the trial will be presented at the 27th Annual North American Cystic Fibrosis Conference in October.

"This was a robust First-in-Human clinical trial assessing safety in 96 subjects. We're very pleased with the safety outcomes of CTX-4430 in this Healthy Volunteer study," said Dr. Ed Philpot, Celtaxsys CMO.  "These results support the continued clinical development of CTX-4430 as a once-daily oral treatment for pulmonary inflammation in CF."

CTX-4430 also exhibited excellent pharmacokinetic and pharmacodynamic properties in this study. "The 100 mg dose achieved maximal effect on its intended target, Leukotriene A4 Hydrolase, for the entire 24 hour period between doses," said Dr. Eric Springman, Celtaxsys CSO. "Having a biomarker to directly probe mechanism of action provides us with a much better understanding of the relationship between dose and effect and will be a tremendous help in the further clinical development of CTX-4430."

Said Mr. Ralph Grosswald, VP of Operations at Celtaxsys, "We had a great experience conducting our initial Phase 1 study of CTX-4430 in Australia. The entire process from start to finish was very efficient and the facilities were second to none."

CTX-4430 will now progress into a Phase 1B trial to assess the safety and pharmacokinetics of once-daily oral treatment for lung disease in Cystic Fibrosis patients.

About Cystic Fibrosis: Cystic Fibrosis is the most common life-shortening autosomal recessive disease among Caucasians, and lung disease is the leading cause of hospitalizations and death in adult CF patients. A hallmark of CF lung disease is excessive recruitment of blood polymorphonuclear neutrophils (PMNs) into the small airways (bronchioles) causing inflammation that results in elastic tissue destruction and progressive loss of lung function.

About CTX-4430: CTX-4430 is a once-daily oral drug candidate currently undergoing clinical trials for treatment of CF lung disease. It is a novel small molecule inhibitor of Leukotriene A4 Hydrolase (LTA4H), the key enzyme in production of the potent inflammatory mediator Leukotriene B4 (LTB4). LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in CF.

About Celtaxsys: Celtaxsys is a privately-held clinical stage drug discovery and development company focused on developing new treatments for inflammatory diseases by modulating innate immunity. The company is building a sustainable pipeline of first-in-class drugs with novel mechanisms of action. For more information, please visit www.celtaxsys.com.


'/>"/>
SOURCE Celtaxsys, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Celtaxsys Restructures, Enhances Operational Focus
2. Freudenberg-NOK Sealing Technologies Announces Screw Connections Based on Hygienic Design Consistently Achievable
3. Plastic Surgeon Dr. Marc J. Salzman Announces Use of Astanza Trinity Laser Tattoo Removal System, Runs Limited-Time Promotion
4. Sam Solakyan announces Paramount Management Services is now a full-scale MSO
5. Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
6. Cell Therapeutics Announces Sale of Convertible Preferred Stock
7. Sangamo BioSciences Announces Presentation of Clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects Treated with SB-728-T
8. Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
9. Aethlon Medical Announces Launch of Exosome Sciences Subsidiary
10. Egalet Announces Financing to Fund Abuse-Deterrent Medications
11. PRA Holdings Announces Proposed Private Offering of $375 Million Senior Notes Due 2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
Breaking Medicine News(10 mins):